Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders. The company's lead investigational new drug candidate is AD04, a genetically targeted serotonin-3 receptor antagonist in Phase 3 clinical trials for the treatment of Alcohol Use Disorder (AUD). Following its acquisition of Azora Therapeutics, its pipeline also includes AT177 for the treatment of ulcerative colitis.
Health
Sector
Freetrade is your gateway to commission-free investing. Join over 1.6 million users using the Best online trading platform, as voted at the British Bank Awards for six years running.
Freetrade does not provide investment advice and individual investors should make their own decisions or seek independent advice. The value of investments can go down as well as up and you may receive back less than your original investment. Past performance is not a reliable indicator of future returns. Freetrade is a trading name of Freetrade Limited, which is a member firm of the London Stock Exchange and is authorised and regulated by the Financial Conduct Authority. Registered in England and Wales (no. 09797821).
© 2026 Freetrade, All rights reserved. The Apple logo is a trademark of Apple Inc. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.
